SCHEMBL14928313

SCHEMBL14928313

CCCOc1nc(Cl)c(C(=O)OC)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.41
PLA2G2A P14555 3/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
GALK1 P51570 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
MAPK8 P45983 1/20 0.34
MAP4K2 Q12851 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14923666 0.89 GRM4 (0.39) CNR1KEAP1NFE2L2HTTRECQL
SCHEMBL14910801 0.89 KEAP1 (0.41) CNR1KEAP1NFE2L2HTTSMN1; SMN2
SCHEMBL393670 0.83 KEAP1 (0.45) KEAP1NFE2L2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL2714981 0.83 GAA (0.38) CNR1KEAP1NFE2L2ALDH1A1CYP1A2
SCHEMBL113592 0.78 KEAP1 (0.62) PLA2G2AKEAP1NFE2L2SMN1; SMN2ALDH1A1
SCHEMBL31459616 0.78 KEAP1 (0.62) PLA2G2AKEAP1NFE2L2SMN1; SMN2ALDH1A1
SCHEMBL27235563 0.76 KEAP1 (0.47) KEAP1NFE2L2SMN1; SMN2KDM4E
SCHEMBL14927568 0.76 KEAP1 (0.39) CNR1KEAP1NFE2L2SMN1; SMN2ALDH1A1
SCHEMBL114292 0.75 KEAP1 (0.46) KEAP1NFE2L2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL14923415 0.75 PGK1 (0.41) KEAP1NFE2L2KDM4EMAP4K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051310-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2015-06-09 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK CNR1 273/4885PLA2G2A 2472/4885KEAP1 1751/4885
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, BTK, NOX4 CNR1 821/4885PLA2G2A 3410/4885KEAP1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.